Cafepharma Today

May 14 2025 - AbbVie pays ADARx $335M cash for next-gen siRNA options
AbbVie pays ADARx $335M cash for next-gen siRNA options
Novo Nordisk inks $2.2B deal for Septerna's preclinical obesity programs
Roche reports final overall survival outcomes from breast cancer treatment trial
GSK buys phase III–ready liver drug in potential $2B deal to play in MASH arena
*please scroll down for all the latest news *

Make it like cafepharma, but for different industries. Learn more about CompanyUnderground

Check open job listings in your area
Click here to stay updated on CP happenings

learn about pharmaceutical fraud
learn about the False Claims Act
learn about clinical lab fraud

Current News

submit a press release

Positive Results for Investigational Compound Lyxumia (Lixisenatide) Presented at American Diabetes Association's 71st Annual Scientific Sessions
Yahoo/PR NewsWire
Saturday, June 25, 2011 - 8:43pm
tags:
Lyxumia, diabetes, Sanofi
Two-Year Data Comparing Cardiovascular Events with Linagliptin and the Sulfonylurea, Glimepiride, Presented as Late-Breaking Poster at ADA
Yahoo/PR NewsWire
Saturday, June 25, 2011 - 8:42pm
tags:
linagliptin, sulfonylurea, glimepiride, diabetes, Boehringer Ingelheim, Eli Lilly
New Phase III Data and Pooled Analysis for Linagliptin Show Improved Blood Sugar Control in Adults With Type 2 Diabetes When Used Alone and With Metformin
Yahoo/PR NewsWire
Saturday, June 25, 2011 - 12:03pm
tags:
linagliptin, Boehringer Ingelheim, Eli Lilly, diabetes
Faruqi & Faruqi, LLP Announces Investigation of Cephalon, Inc.
Yahoo/BusinessWire
Saturday, June 25, 2011 - 12:01pm
tags:
Cephalon
Pacific Biosciences—A Spec Stock Worth the Risk?
CNBC
Saturday, June 25, 2011 - 11:59am
tags:
Pacific Biosciences, DNA sequencing
AIDS Research Alliance to test GeoVax HIV vaccine
bizjournals.com
Saturday, June 25, 2011 - 11:57am
tags:
GeoVax Labs, HIV
Halozyme's Ultrafast Insulin Demonstrates Reduced Variability of Insulin Absorption for Type 1 Diabetes Patients Using Insulin Pumps
Yahoo/PR NewsWire
Saturday, June 25, 2011 - 11:56am
tags:
Halozyme, Aspart-PH20, Novolog, insulin pumps, diabetes
Analysis Finds Byetta Associated with Lower Likelihood of Heart Failure Compared with Other Diabetes Therapies: Results Presented at ADA 2011
Yahoo/PR NewsWire
Saturday, June 25, 2011 - 11:53am
tags:
Byetta, Amylin, diabetes
Ozone Pharma gets patent for molecule of diabetic retinopathy
Pharmabiz
Saturday, June 25, 2011 - 11:51am
tags:
Ozone Pharma, diabetic retinopathy
Zafgen Announces Cardiovascular Data from Phase 1b Study of ZGN-433 in Obesity at American Diabetes Association Annual Meeting
Enhanced Online News
Saturday, June 25, 2011 - 11:25am
tags:
Zafgen, ZGN-433, obesity, weight loss
GlaxoSmithKline - Best Performing Pharmaceutical
Trader's Huddle
Saturday, June 25, 2011 - 11:22am
tags:
GSK
Takeda's Actos, Glaxo's Avandia Raise Risk of Eye Disease
San Francisco Gate, CA
Saturday, June 25, 2011 - 11:22am
tags:
Takeda, Actos, GSK, Avandia, macular edema, diabetes
Supreme Court Provides Immediate Relief for Drug Firms
Fair Warning
Saturday, June 25, 2011 - 11:05am
tags:
legal, generics, drug marketing
Abbott Reveals Positive Results From Phase-2 Trial Of Kidney Drug
RTT News
Saturday, June 25, 2011 - 11:03am
tags:
Abbott Laboratories, bardoxolone methyl, chronic kidney disease
Aoxing Pharmaceutical Company Has No Comment on Unusual Trading Activity
Bradenton Herald, FL
Saturday, June 25, 2011 - 11:00am
tags:
Aoxing
Analysis Provides New Insights Into Use of Symlin in Patients With Type 1 Diabetes Using Insulin Pumps
Yahoo/PR NewsWire
Saturday, June 25, 2011 - 10:41am
tags:
Symlin, insulin pumps, diabetes, Amylin
Studies Show No Increased Risk of Cardiac Events in Diabetes Patients Treated with Afrezza
Yahoo/BusinessWire
Saturday, June 25, 2011 - 10:39am
tags:
Afrezza, MannKind, insulin, diabetes
FDA recommends lower doses of anemia drugs
Yahoo/AP
Saturday, June 25, 2011 - 10:37am
tags:
Aranesp, Procrit, Epogen, chronic kidney disease
Clovis Oncology files $149.5M IPO
bizjournals.com
Saturday, June 25, 2011 - 10:36am
tags:
Clovis Oncology, IPOs
Amgen Announces Modifications to U.S. Prescribing Information for Use of Erythropoiesis-Stimulating Agents in Chronic Kidney Disease
Yahoo/PR NewsWire
Saturday, June 25, 2011 - 10:35am
tags:
Amgen, Aranesp, Epogen, chronic kidney disease

Pages

Latest CP Wire Articles

Hermes Intelligence Launches to Redefine Pharma Data Solutions [sponsored]
The Evolution of Medical Sales: What’s Changing in 2025?
FDA Scraps Key Vaccine Meetings—What It Means for Manufacturers
FDA approves Danziten, the first nilotinib treatment for Ph+ CML with no mealtime restrictions
Daily U.S. Flu Cases Expected to Nearly Double from Last Year by Late November, Predicts Novel Mathematical Forecasting Tool
PharmaBlock Receives 2024 ACS CMO Excellence in Green Chemistry Award, Marking a Second Consecutive Year of Recognition
Leading Clinical Research Network Centricity Research Acquires North Carolina-based Lucas Research
First-of-Its-Kind Alzheimer’s Disease Simulation Paves Way for Personalized Treatment: Penn State, Duke University Study
Centricity Research Appoints New CEO, CFO to Support Next Phase of Growth
Sermo Barometer Examines Influencers’ Impact on Patient Perceptions of Weight Loss Medications & Preventative Care Technologies

Latest Pharmagather Articles

New Cell Therapy For Resistant Hodgkins Patients
In the Pipeline
Escape From the Lysosome
In the Pipeline
Heavy Water in Your NMR Experiments, And Elsewhere
In the Pipeline
GIPR: Agonists and Antagonists Do the Same Thing, But How
In the Pipeline
Mutant Proteins Classified
In the Pipeline
The Continuing Crisis, Part XIV: The Trumpist Worldview
In the Pipeline
Whole Lotta Snakin' Going On
In the Pipeline
The GLP-1 Saga Continues, And How
In the Pipeline
Defluorination is Happening Inside You Right Now
In the Pipeline

current feelings about your job

Please rate how you feel about your job this moment. 1 = "I hate my job" and 7 = "I love my job"
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Fill in the blank.